Author(s): DONG Zhong-yi, ZHONG Wen-zhao, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute
Pages: 135+142
Year: 2016 Issue:  3
Journal: Journal of Evidence-Based Medicine
Keyword:  neoplasms; immunotherapy; acquired resistance; T-cell immunoglobulin mucin-3(TIM-3); programmed cell death protein 1(PD-1);
Abstract: <正>近日一篇发表在《Nature Communication》杂志上阐述抗PD-1免疫治疗获得性耐药机制的文章受到读者广泛关注。该文首次报道,抗PD-1免疫治疗发生耐药的主要机制是选择性激活新的免疫检查点TIM3(T cell immunoglobulin domainand mucindomain 3)从而导致免疫逃逸。该研究的发现也受到了许多肿瘤免疫治疗领域专家们的重视,Romero教授对该文进行了点评,并发表在《NatRev Clin Oncol》上。抗PD-1免疫治疗获得性耐药